Celia A. Schiffer

Celia A. Schiffer's AcademicInfluence.com Rankings

Celia A. Schiffer

Biology

#12663

World Rank

#16154

Historical Rank

#2649

USA Rank

Biochemistry

#2175

World Rank

#2320

Historical Rank

#304

USA Rank

biology Degrees

Download Badge

Biology

Celia A. Schiffer's Degrees

Bachelors Chemistry University of California, Berkeley

Why Is Celia A. Schiffer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Celia A. Schiffer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Proton Sponge: a Trick to Enter Cells the Viruses Did Not Exploit (1997) (490)
Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. (2002) (317)
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). (1992) (296)
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. (2005) (253)
Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments (2003) (241)
Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor (2004) (237)
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors (2012) (206)
Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. (1986) (200)
Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. (2000) (196)
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). (2001) (194)
Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding (2010) (186)
How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. (2000) (173)
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations (2021) (170)
A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. (1991) (168)
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia (1994) (156)
Combating susceptibility to drug resistance: lessons from HIV-1 protease. (2004) (142)
Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. (1999) (140)
Viral Protease Inhibitors (2009) (133)
Molecular Basis for Drug Resistance in HIV-1 Protease (2010) (131)
Replacement of the P1 Amino Acid of Human Immunodeficiency Virus Type 1 Gag Processing Sites Can Inhibit or Enhance the Rate of Cleavage by the Viral Protease (2002) (123)
Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. (2010) (121)
PTEN enters the nucleus by diffusion (2005) (118)
Alloimmunization following platelet transfusion: the absence of a dose- response relationship (1981) (117)
Influenza Virus Drug Resistance: A Time-Sampled Population Genetics Perspective (2014) (114)
Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5 (2008) (114)
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. (2008) (113)
First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. (2012) (113)
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. (1993) (112)
Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug Resistance (2010) (111)
Methylcytosine and Normal Cytosine Deamination by the Foreign DNA Restriction Enzyme APOBEC3A* (2012) (109)
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction (2020) (108)
Structural Basis for Coevolution of a Human Immunodeficiency Virus Type 1 Nucleocapsid-p1 Cleavage Site with a V82A Drug-Resistant Mutation in Viral Protease (2004) (107)
Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity (2017) (103)
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. (2008) (101)
Lack of synergy for inhibitors targeting a multi‐drug‐resistant HIV‐1 protease (2002) (97)
Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site. (1995) (96)
Covariation of amino acid positions in HIV-1 protease. (2003) (95)
Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy (2003) (91)
Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. (2007) (91)
Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain. (2013) (90)
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. (2006) (89)
Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease. (2012) (84)
Drug Resistance Conferred by Mutations Outside the Active Site through Alterations in the Dynamic and Structural Ensemble of HIV-1 Protease (2014) (82)
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. (1998) (80)
The ssDNA Mutator APOBEC3A Is Regulated by Cooperative Dimerization. (2015) (80)
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. (1994) (77)
Improving Viral Protease Inhibitors to Counter Drug Resistance. (2016) (74)
Structure of the Vif-binding domain of the antiviral enzyme APOBEC3G (2015) (73)
Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. (2011) (71)
Mechanism of Substrate Recognition by Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variants Revealed by a Novel Structural Intermediate (2006) (68)
Contribution of Ser386 and Ser396 to activation of interferon regulatory factor 3. (2008) (68)
Structural basis for mutation-induced destabilization of profilin 1 in ALS (2015) (68)
Hydrophobic core flexibility modulates enzyme activity in HIV-1 protease. (2012) (65)
Citrullination of NF-κB p65 promotes its nuclear localization and TLR-induced expression of IL-1β and TNFα (2017) (65)
Therapeutic targeting of C-terminal binding protein in human cancer (2010) (64)
Protein structure prediction with a combined solvation free energy-molecular mechanics force field (1993) (64)
Nitric oxide-mediated inhibition of Hdm2-p53 binding. (2002) (64)
Design of HIV-1 protease inhibitors active on multidrug-resistant virus. (2005) (64)
Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. (2013) (62)
Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. (2006) (60)
Differential Flap Dynamics in Wild-type and a Drug Resistant Variant of HIV-1 Protease Revealed by Molecular Dynamics and NMR Relaxation. (2012) (60)
Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance (2009) (59)
Evaluation of the substrate envelope hypothesis for inhibitors of HIV‐1 protease (2007) (58)
Design of Mutation‐resistant HIV Protease Inhibitors with the Substrate Envelope Hypothesis (2007) (57)
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. (2013) (57)
Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188 (2021) (56)
Stabilization of Type-I .beta.-Turn Conformations in Peptides Containing the NPNA-Repeat Motif of the Plasmodium falciparum Circumsporozoite Protein by Substituting Proline for (S)-.alpha.-Methylproline (1995) (56)
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors (2008) (55)
The role of protein-solvent interactions in protein unfolding. (1996) (54)
Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. (2007) (54)
Mass spectrometry analysis of HIV‐1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity (2007) (54)
Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease (2014) (53)
Cooperative fluctuations of unliganded and substrate‐bound HIV‐1 protease: A structure‐based analysis on a variety of conformations from crystallography and molecular dynamics simulations (2003) (53)
Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones. (2010) (52)
Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease. (2016) (52)
Evolution of the Influenza A Virus Genome during Development of Oseltamivir Resistance In Vitro (2013) (51)
Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. (1996) (51)
Inclusion of solvation free energy with molecular mechanics energy: Alanyl dipeptide as a test case (1992) (50)
Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA (2018) (49)
Prediction of homologous protein structures based on conformational searches and energetics (1990) (46)
Molecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A Protease (2011) (46)
Decomposing the energetic impact of drug resistant mutations in HIV-1 protease on binding DRV. (2010) (45)
Context Surrounding Processing Sites Is Crucial in Determining Cleavage Rate of a Subset of Processing Sites in HIV-1 Gag and Gag-Pro-Pol Polyprotein Precursors by Viral Protease* (2012) (44)
Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV‐1 protease (2008) (44)
Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance. (2012) (42)
Clinical evaluation of platelet concentrates stored for one to five days (1986) (42)
Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease (2014) (42)
Role of Invariant Thr80 in Human Immunodeficiency Virus Type 1 Protease Structure, Function, and Viral Infectivity (2006) (40)
Substrate sequence selectivity of APOBEC3A implicates intra-DNA interactions (2017) (40)
Three Residues in HIV-1 Matrix Contribute to Protease Inhibitor Susceptibility and Replication Capacity (2010) (40)
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies (2021) (38)
Accounting for molecular mobility in structure determination based on nuclear magnetic resonance spectroscopic and X-ray diffraction data. (1994) (38)
Testing the Substrate-Envelope Hypothesis with Designed Pairs of Compounds (2013) (38)
Improving the Resistance Profile of Hepatitis C NS3/4A Inhibitors: Dynamic Substrate Envelope Guided Design. (2013) (38)
High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients (1984) (38)
Competition between Ski and CREB-binding Protein for Binding to Smad Proteins in Transforming Growth Factor-β Signaling* (2007) (37)
Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side (2017) (37)
CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy (2017) (37)
The Effect of Clade-Specific Sequence Polymorphisms on HIV-1 Protease Activity and Inhibitor Resistance Pathways (2010) (37)
A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance. (2016) (37)
Drug Resistance Mutations Alter Dynamics of Inhibitor-Bound HIV-1 Protease (2014) (36)
Substrate Envelope and Drug Resistance: Crystal Structure of RO1 in Complex with Wild-Type Human Immunodeficiency Virus Type 1 Protease (2006) (35)
APOBEC3s: DNA‐editing human cytidine deaminases (2019) (35)
Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 Protease (2007) (34)
Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172. (2016) (34)
Point mutants of EHEC intimin that diminish Tir recognition and actin pedestal formation highlight a putative Tir binding pocket (2002) (33)
Mutations in Influenza A Virus Neuraminidase and Hemagglutinin Confer Resistance against a Broadly Neutralizing Hemagglutinin Stem Antibody (2018) (33)
Assembly of human C-terminal binding protein (CtBP) into tetramers (2018) (33)
Simultaneous refinement of the structure of BPTI against NMR data measured in solution and X-ray diffraction data measured in single crystals. (1994) (31)
Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design (2014) (31)
Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants. (2017) (31)
Structural and Thermodynamic Basis of Amprenavir/Darunavir and Atazanavir Resistance in HIV-1 Protease with Mutations at Residue 50 (2013) (31)
TMC310911, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro an Improved Resistance Profile and Higher Genetic Barrier to Resistance Compared with Current Protease Inhibitors (2011) (30)
Genome scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes (2020) (29)
Efficient Computation of Small-Molecule Configurational Binding Entropy and Free Energy Changes by Ensemble Enumeration (2013) (28)
Structure of a phage display-derived variant of human growth hormone complexed to two copies of the extracellular domain of its receptor: evidence for strong structural coupling between receptor binding sites. (2002) (28)
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. (2006) (27)
Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms (2022) (27)
The challenge of developing robust drugs to overcome resistance. (2011) (26)
A computational analysis of the structural determinants of APOBEC3's catalytic activity and vulnerability to HIV-1 Vif. (2014) (26)
Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1 (2013) (26)
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit (2021) (26)
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance (2022) (26)
Accessibility and order of water sites in and around proteins: A crystallographic time‐averaging study (1999) (25)
Interdependence of Inhibitor Recognition in HIV-1 Protease (2017) (24)
Structure-guided design of a high affinity inhibitor to human CtBP. (2015) (24)
Toward the Design of Mutation‐Resistant Enzyme Inhibitors: Further Evaluation of the Substrate Envelope Hypothesis (2009) (24)
Introduction: Drug Resistance. (2021) (24)
The interdomain interface in bifunctional enzyme protein 3/4A (NS3/4A) regulates protease and helicase activities (2013) (23)
Additivity in the analysis and design of HIV protease inhibitors. (2009) (23)
Time-averaging crystallographic refinement: possibilities and limitations using alpha-cyclodextrin as a test system. (1995) (23)
Hydration Structure and Dynamics of Inhibitor-Bound HIV-1 Protease. (2018) (23)
Elucidating the Interdependence of Drug Resistance from Combinations of Mutations. (2017) (22)
Investigation of protein unfolding and stability by computer simulation. (1995) (22)
Molecular Basis for Differential Patterns of Drug Resistance in Influenza N1 and N2 Neuraminidase. (2016) (21)
HIV-1 Protease and Substrate Coevolution Validates the Substrate Envelope As the Substrate Recognition Pattern. (2012) (21)
Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease. (2018) (21)
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. (2021) (21)
Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. (2018) (21)
HIV-1 Protease-Substrate Coevolution in Nelfinavir Resistance (2014) (21)
Exploring the role of the solvent in the denaturation of a protein: a molecular dynamics study of the DNA binding domain of the 434 repressor. (1995) (21)
IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity (2020) (20)
Structure-based prediction of potential binding and nonbinding peptides to HIV-1 protease. (2003) (19)
Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. (2013) (19)
Positive Selection Drives Preferred Segment Combinations during Influenza Virus Reassortment. (2015) (18)
Structural insights into neuronal K+ channel–calmodulin complexes (2012) (17)
Structural, kinetic, and thermodynamic studies of specificity designed HIV‐1 protease (2012) (17)
pM to µM - Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance. (2019) (16)
Structural analysis of the active site and DNA binding of human cytidine deaminase APOBEC3B (2018) (16)
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors (2023) (15)
HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands to Optimize Hydrogen Bonding in the Substrate Envelope. (2019) (15)
Dengue Protease Substrate Recognition: Binding of the Prime Side. (2016) (15)
Synonymous Mutations at the Beginning of the Influenza A Virus Hemagglutinin Gene Impact Experimental Fitness. (2018) (15)
Target-Specific Prediction of Ligand Affinity with Structure-Based Interaction Fingerprints (2019) (14)
Viability of a drug-resistant HIV-1 protease mutant: structural insights for better antiviral therapy (2003) (14)
The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients (1984) (14)
Association of a Novel Human Immunodeficiency Virus Type 1 Protease Substrate Cleft Mutation, L23I, with Protease Inhibitor Therapy and In Vitro Drug Resistance (2004) (14)
Characterizing protein-ligand binding using atomistic simulation and machine learning: Application to drug resistance in HIV-1 protease. (2019) (13)
Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope (2017) (13)
Molecular determinants of epistasis in HIV-1 protease: Elucidating the interdependence of L89V and L90M mutations in resistance. (2019) (13)
Structural Analysis of Human Immunodeficiency Virus Type 1 CRF01_AE Protease in Complex with the Substrate p1-p6 (2008) (13)
Substrate specificity in HIV‐1 protease by a biased sequence search method (2006) (12)
Viral proteases: Structure, mechanism and inhibition (2021) (12)
Quinoxaline-Based Linear HCV NS3/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants. (2018) (12)
Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode (2021) (12)
Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance (2012) (12)
The structural and thermodynamic basis for the binding of TMC114, a next-generation HIV-1 protease inhibitor. (2005) (11)
A Direct Interaction with RNA Dramatically Enhances the Catalytic Activity of the HIV-1 Protease In Vitro. (2015) (11)
Probing Structural Changes among Analogous Inhibitor-Bound Forms of HIV-1 Protease and a Drug-Resistant Mutant in Solution by Nuclear Magnetic Resonance. (2018) (11)
Investigations of peptide hydration using NMR and molecular dynamics simulations: A study of effects of water on the conformation and dynamics of antamanide (1996) (11)
Resistance outside the substrate envelope: hepatitis C NS3/4A protease inhibitors (2019) (11)
Promise of advances in simulation methods for protein crystallography: implicit solvent models, time-averaging refinement, and quantum mechanical modeling. (2003) (11)
Combating Susceptibility to Drug ResistanceLessons from HIV-1 Protease (2004) (11)
Crystallization of human thymidylate synthase. (1991) (10)
Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors (2020) (10)
HIV-1 Protease Uses Bi-Specific S2/S2’ Subsites To Optimize Cleavage of Two Classes of Target Sites (2018) (10)
Crystal structure of a soluble APOBEC3G variant suggests ssDNA to bind in a channel that extends between the two domains. (2020) (10)
RecA dimers serve as a functional unit for assembly of active nucleoprotein filaments. (2006) (10)
Cryo-EM Structure of CtBP2 Confirms Tetrameric Architecture. (2020) (10)
Inhibition of APOBEC3G activity impedes double‐stranded DNA repair (2016) (10)
Rationale for more diverse inhibitors in competition with substrates in HIV-1 protease. (2010) (9)
Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy. (2015) (9)
Structural stability of disulfide mutants of basic pancreatic trypsin inhibitor: A molecular dynamics study (1996) (9)
Mavyret: A Pan-Genotypic Combination Therapy for the Treatment of Hepatitis C InfectionPublished as part of the Biochemistry series "Biochemistry to Bedside". (2017) (9)
Constrained mutational sampling of amino acids in HIV-1 protease evolution (2018) (9)
Management of patients refractory to platelet transfusion--an evaluation of methods of donor selection. (1987) (9)
T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response (2018) (8)
Decomposing the energetic impact of drug-resistant mutations: the example of HIV-1 protease-DRV binding. (2012) (8)
Quantitative comparison of errors in 15N transverse relaxation rates measured using various CPMG phasing schemes (2012) (8)
Methyl-and Normal-Cytosine Deamination by the Foreign DNA Restriction Enzyme APOBEC 3 A (2012) (8)
Structural and molecular analysis of a protective epitope of Lyme disease antigen OspA and antibody interactions (2017) (8)
Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. (2021) (8)
A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid. (2013) (7)
Unique structural solution from a VH3-30 antibody targeting the hemagglutinin stem of influenza A viruses (2021) (7)
Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir (2019) (7)
Avoiding Drug Resistance by Substrate Envelope Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors (2020) (6)
Drug Resistance to HIV-1 Protease Inhibitors: Molecular Mechanisms and Substrate Coevolution (2017) (6)
Modulation of HIV protease flexibility by the T80N mutation (2015) (6)
Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA (2019) (6)
Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs (2014) (6)
Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution (2015) (6)
COVID-19 Research (2020) (6)
NAD(H) phosphates mediate tetramer assembly of human C-terminal binding protein (CtBP) (2021) (5)
Dengue Virus NS 2 B / NS 3 Protease Inhibitors Exploiting the Prime Side Authors (2017) (5)
NMR and MD studies combined to elucidate inhibitor and water interactions of HIV-1 protease and their modulations with resistance mutations (2019) (5)
Morphologic characteristics of acute lymphoblastic leukemia (ALL) with abnormalities of chromosome 8, band q24 (1992) (5)
Structural basis of substrate specificity in human cytidine deaminase family APOBEC3s (2021) (5)
Inhibiting HTLV-1 Protease: A Viable Antiviral Target. (2021) (5)
Interactions of APOBEC3s with DNA and RNA. (2021) (5)
The impact of thrombopoietin and related Mpl-ligands on transfusion medicine. (1997) (4)
Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance (2019) (4)
Erratum: Covariation of amino acid positions in HIV-1 protease (Virology (2003) 314 (536-548) PII: S0042-6822(03)00484-7 and DOI: 10.1016/S0042-6822(03) 00484-7) (2005) (4)
Combating Drug Resistance – Identifying Resilient Molecular Targets and Robust Drugs (2007) (4)
Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-Tetrahydrofuran in a Pseudo-Symmetric Dipeptide Isostere. (2020) (4)
Deciphering complex mechanisms of resistance and loss of potency through coupled molecular dynamics and machine learning (2020) (4)
Molecular mechanisms of viral and host-cell substrate recognition by HCV NS3/4A protease (2011) (4)
Mass spectrometry tools for analysis of intermolecular interactions. (2012) (4)
REdiii: a pipeline for automated structure solution. (2015) (3)
Expression, purification, and characterization of thymidylate synthase from Lactococcus lactis (1994) (3)
Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance. (2022) (3)
Resistance from Afar: Distal Mutation V36M Allosterically Modulates the Active Site to Accentuate Drug Resistance in HCV NS3/4A Protease (2018) (3)
A call to arms: Unifying the fight against resistance (2018) (3)
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants (2022) (3)
Interview with Celia Schiffer. (2013) (3)
Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2 (2022) (2)
Crystal structure of the APOBEC3G catalytic domain (2010) (2)
Antibody Fab Fragment (2017) (2)
Analyses of HIV proteases variants at the threshold of viability reveals relationships between processing efficiency and fitness (2021) (2)
Integrating Evolution of Drug Resistance into Drug Discovery (2020) (2)
Non-canonical pattern recognition of a pathogen-derived metabolite by a nuclear hormone receptor identifies virulent bacteria in C. elegans. (2023) (2)
Deciphering Antifungal Drug Resistance in Pneumocystis jirovecii DHFR with Molecular Dynamics and Machine Learning (2021) (2)
Quantitative Structural Analysis of Influenza Virus by Cryo-electron Tomography and Convolutional Neural Networks (2021) (2)
Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning. (2021) (2)
HIV protease wild-type in complex with TMC114 inhibitor (2005) (1)
Time-Averaging Crystallographic Refinement (1997) (1)
Structure of the catalytically active APOBEC3G bound to a DNA oligonucleotide inhibitor reveals tetrahedral geometry of the transition state (2022) (1)
Quantitative structural analysis of influenza virus by cryo-electron tomography and convolutional neural networks. (2022) (1)
Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in HIV-1 Protease (2007) (1)
Substrate envelope and drug resistance: crystal structure of r01 in complex with wild-type hiv-1 protease (2006) (1)
Challenge of Alloimmunization and Refractoriness to Platelet Transfusion (1997) (1)
PHAGE DISPLAY DERIVED VARIANT OF HUMAN GROWTH HORMONE COMPLEXED WITH TWO COPIES OF THE EXTRACELLULAR DOMAIN OF ITS RECEPTOR (2002) (1)
Avoiding drug resistance against HCV NS3/4A protease inhibitors (2010) (1)
Structural Explanations to Altered Drug Resistance Pathways in HIV-1 Non-Clade B Proteases (2009) (1)
Optimizing the refinement of merohedrally twinned P61 HIV-1 protease-inhibitor cocrystal structures. (2020) (1)
Crystal structure of inhibitor saquinavir (SQV) in complex with multi-drug resistant HIV-1 protease (L63P/V82T/I84V) (referred to as ACT in paper) (2009) (1)
116 Deamination of both methyl- and normal-cytosine by the foreign DNA restriction enzyme APOBEC3A (2013) (1)
HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, A71V, L76V, V82F, I84V Mutant in complex with darunavir (2019) (0)
CryoEM Structure of CtBP2 Confirms Tetrameric Architecture [preprint] (2021) (0)
HCV NS3/4A protease domain of genotype 1a in complex with glecaprevir (2020) (0)
Crystal structure of nelfinavir (NFV) complexed with a multidrug variant (ACT) (V82T/I84V) of HIV-1 protease (2009) (0)
Crystal structure of HIV-1 protease inhibitor, KC32 complexed with wild-type protease (2010) (0)
Crystal Structure of wild-type HIV-1 Protease in Complex with MKP86 (2012) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with NR04-49 (2021) (0)
Crystal structure of protease inhibitor, KB62 in complex with wild type HIV-1 protease (2010) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-2 (NR02-61) (2020) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with NR02-59 (2021) (0)
Crystal structure of HIV-1 Protease NL4-3 WT in complex with UMass6 (2018) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-5 (NR01-97) (2020) (0)
Crystal Structure of wild-type HIV-1 Protease in complex with kd27 (2011) (0)
Crystal structure of HCV NS3/4A WT protease in complex with AJ-50 (MK-5172 linear analogue) (2018) (0)
Constraining evolution → avoiding drug resistance: lessons from viruses (2020) (0)
CtBP1 in complex with substrate MTOB (2014) (0)
Crystal structure of HCV NS3/4A protease in complex with P4-P5-1 (WK-23) (2019) (0)
Crystal Structure of wild-type HIV-1 Protease in complex with kd20 (2011) (0)
HIV-1 Protease NL4-3 WT in Complex with LR3-43 (2020) (0)
Crystal Structure of HIV-1 I50V, A71V Protease in Complex with the Protease Inhibitor Atazanavir (2011) (0)
Structural Determination o f the Broadly Reactive Anti-IGHV 169 Anti-idiotypic Antibody G 6 and Its Idiotope Graphical Abstract Highlights (2017) (0)
Crystal structure of HCV NS3/4A WT protease in complex with AJ-21 (MK-5172 linear analogue) (2018) (0)
Crystal structure of wild-type inactive (D25N) HIV-1 protease complexed with wild-type HIV-1 NC-p1 substrate. (2006) (0)
Crystal structure of protease inhibitor, AD78 in complex with wild type HIV-1 protease (2010) (0)
Crystal Structure of wild-type HIV-1 Protease in Complex with kd25 (2011) (0)
HCV NS3/4A protease A156T, D168E double mutant in complex with glecaprevir (2020) (0)
Crystal structure of inactive HIV-1 protease in complex with p1-p6 substrate variant (P453L) (2014) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-5 (WK-25) (2020) (0)
HCV NS3/4A protease A156T, D168E double mutant (2020) (0)
Crystal structure of HCV NS3/4A protease in complex with P4-3(AJ-74) (2019) (0)
Tetrameric Assembly of the Oncogenic C-Terminal Binding Proteins (2019) (0)
Crystal Structure of HCV NS3/4A protease in complex with an Asunaprevir P1-P3 macrocyclic analog. (2014) (0)
HCV NS3/4A protease domain of genotype 1a C159 in complex with glecaprevir (2020) (0)
Molecular and structural mechanism of pan-genotypic HCV NS3/4A protease inhibition by glecaprevir [preprint] (2020) (0)
Using Molecular Dynamics to Investigate Substrate Recognition and Co-evolution in HIV-1 Protease (2009) (0)
Crystal structure of HCV NS3/4A double mutant variant Y56H/D168A in complex with danoprevir (2019) (0)
Crystal Structure of wild-type HIV-1 Protease in complex with af53 (2011) (0)
MassTERi: Promoting Translational Research and Entrepreneurship at the University of Massachusetts Medical School (2014) (0)
Crystal Structure of wild-type HIV-1 Protease in Complex with MKP97 (2012) (0)
Crystal structure of I50L/A71V mutant of hiv-1 protease in complex with inhibitor darunavir (2009) (0)
CtBP2 in complex with substrate MTOB (2014) (0)
Crystal structure of inactive HIV-1 protease variant (I50V/A71V) in complex with p1-p6 substrate variant (L449F) (2014) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-32 (2020) (0)
HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, L76V, V82F, I84V Mutant in complex with darunavir (2019) (0)
Crystal structure of amprenavir (APV) in complex with a drug resistant HIV-1 protease variant (I50L/A71V). (2009) (0)
Crystal Structure of Broadly Neutralizing Antibody 3I14 Bound to the Influenza A H3 Hemagglutinin (2020) (0)
Substrate sequence selectivity of APOBEC3A implicates intra-DNA interactions (2018) (0)
Crystal structure of wild-type HIV-1 protease in complex with AF55 (2012) (0)
Crystal structure of atazanavir (ATV) in complex with a multidrug HIV-1 protease (V82T/I84V) (2009) (0)
The Effect of Clade-Speciﬁc Sequence Polymorphisms on HIV-1 Protease Activity and Inhibitor Resistance Pathways (cid:1) (2010) (0)
Crystal structure of NS3/4A protease variant A156T in complex with danoprevir (2012) (0)
HIV-1 Protease NL4-3 K45I, M46I, V82F, I84V Mutant in complex with darunavir (2019) (0)
Crystal Structure of Human APOBEC3A (2015) (0)
Crystal Structure of wild-type HIV protease in complex with the inhibitor, Atazanavir (2009) (0)
HIV-1 Protease NL4-3 WT in Complex with UMass3 (2019) (0)
HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, V82F, I84V Mutant in complex with darunavir (2019) (0)
Crystal structure of HCV NS3/4A protease variant Y56H in complex with danoprevir (2019) (0)
CRYSTAL STRUCTURE OF DECAMER NCP1 SUBSTRATE PEPTIDE IN COMPLEX WITH WILD-TYPE D25N HIV-1 PROTEASE VARIANT (2005) (0)
Structural Comparison of Firefly Luciferase with the Latent Luciferase CG6178 (2015) (0)
HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, I54L, A71V, L76V, V82F, I84V Mutant in complex with darunavir (2019) (0)
Activation Of Interferon Regulatory Factors Revealed By The Crystal Structure Of Dimeric IRF-5 (2009) (0)
Crystal structure of HCV NS3/4A protease in complex with N-terminal product 4B5A (2010) (0)
Crystal Structure of wild-type HIV-1 Protease in complex with kd14 (2011) (0)
Structure of HIV-1 protease D25N complexed with the rt-rh analogue peptide GLY-ALA-GLN-THR-PHE*TYR-VAL-ASP-GLY-ALA (2007) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-44 (2020) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-25 (2019) (0)
HIV-1 Protease NL4-3 WT in Complex with LR-82 (2019) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-43 (2020) (0)
CRYSTAL STRUCTURE OF AP2V SUBSTRATE VARIANT OF NC-P1 DECAMER PEPTIDE IN COMPLEX WITH V82A/D25N HIV-1 PROTEASE MUTANT (2005) (0)
Crystal structure of NS3/4A protease in complex with MK-5172 (2012) (0)
Structural Determination of the Broadly Reactive Anti-IGHV 169 Anti-idiotypic Antibody G 6 and Its Idiotope Graphical (2018) (0)
Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease (2023) (0)
HIV-1 Protease NL4-3 V82F, I84V Mutant in complex with darunavir (2019) (0)
Crystal structure of HCV NS3/4A protease in complex with P4-1 (AJ-71) (2019) (0)
Crystal structure of HCV NS3/4A protease in complex with P4-P5-2 (AJ-67) (2019) (0)
Structural Analysis of Human Immunodeﬁciency Virus Type 1 CRF01_AE Protease in Complex with the Substrate p1-p6 (cid:1) (2008) (0)
Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease. (2022) (0)
HCV NS3/4A protease domain of genotype 4a with an extended linker in complex with glecaprevir (2020) (0)
HCV NS3/4A protease domain of genotype 4a in complex with glecaprevir (2020) (0)
Human Immunodeﬁciency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance (cid:1) § (2009) (0)
Crystal structure of a genotype 1a/3a chimeric HCV NS3/4A protease in complex with Asunaprevir (2016) (0)
Correction to Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease. (2019) (0)
Crystal structure of atazanavir (ATV) in complex with I50L/A71V drug-resistant HIV-1 protease (2009) (0)
Crystal structure of HIV-1 Protease NL4-3 I84V Mutant in complex with darunavir (2018) (0)
Crystal structure of HIV-1 protease inhibitor KC53 in complex with wild-type protease (2010) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-2 (AJ-67) (2019) (0)
HIV-1 Protease NL4-3 WT in Complex with LR-100 (2019) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-19 (2019) (0)
Crystal Structure of apo(G16C/L38C) HIV-1 Protease (2012) (0)
Synthesis and Biological Evaluation of 4/5‐Aroyl‐2‐aminoimidazoles as Microbial Biofilm Inhibitors (2020) (0)
Crystal Structure of the active HIV-1 Protease in Complex with the products of p1-p6 substrate (2013) (0)
HCV NS3/4A protease domain of genotype 1a3a chimera in complex with grazoprevir (2020) (0)
Crystal structure of inhibitor saquinavir (SQV) complexed with the multidrug HIV-1 protease variant L63P/V82T/I84V (2009) (0)
Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA (2018) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-6 (NR03-68) (2020) (0)
HIV-1 Protease NL4-3 WT in complex with darunavir (2019) (0)
Crystal structure of wild-type HIV-1 protease in complex with AF69 (2012) (0)
Call for Papers: Drug Resistance in Infectious Diseases and Beyond. (2022) (0)
Crystal structure of HCV NS3/4A protease in complex with ITMN-191 (2010) (0)
Crystal Structure of wild-type HIV-1 Protease in Complex with MKP56 (2012) (0)
Crystal structure of HCV NS3/4A protease in complex with P4-2 (JZ01-19) (2019) (0)
A representation of a possible intermediate step during substrate recognition of HIV-1 protease: crystal structures of substrate bound enzyme exhibiting a novel flap conformation (2005) (0)
HIV-1 Protease NL4-3 WT in Complex with UMass8 (2019) (0)
Structure of HIV-1 protease D25N complexed with rt-rh analogue peptide GLY-ALA-ASP-ILE-PHE*TYR-LEU-ASP-GLY-ALA (2007) (0)
Crystal structure of HCV NS3/4A WT protease in complex with AJ-52 (MK-5172 linear analogue) (2018) (0)
Improving Viral Protease Inhibitors to Counter Drug (2016) (0)
Crystal structure of HCV NS3/4A WT protease in complex with 5172-Linear (MK-5172 linear analogue) (2016) (0)
HIV-1 Protease NL4-3 L89V, L90M Mutant in complex with darunavir (2019) (0)
Remembering Professor Amy Christine Anderson (2016) (0)
Crystal Structure of HIV-1 CRF01_AE in complex with the substrate p1-p6 (2008) (0)
Crystal Structure of Broadly Neutralizing Antibody 3I14-D93N Mutant Bound to the Influenza A H6 Hemagglutinin (2020) (0)
Crystal Structure of wild-type HIV-1 Protease in complex with af61 (2011) (0)
Crystal structure of wild-type HIV-1 protease in complex with AF78 (2012) (0)
Crystal structure of HIV-1 Protease NL4-3 WT in complex with UMass1 (2018) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-20 (2019) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-1 (NR02-24) (2020) (0)
HCV NS3/4A protease domain of genotype 1a3a chimera in complex with glecaprevir (2020) (0)
Crystal Structure of Wild-type HIV-1 Protease in Complex With TMC310911 (2011) (0)
Structure of Nelfinavir-resistant HIV-1 protease (D30N/N88D) in complex with Darunavir. (2010) (0)
Mutations Outside the Active Site of HIV-1 Protease Alter Enzyme Structure and Dynamic Ensemble of the Active Site to Confer Drug Resistance (2015) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with PC (JZ01-15) (2020) (0)
Abstract 2107: Characterizing influenza virus entry using cryo-electron tomography and convolutional neural networks (2023) (0)
Structural Mechanism of Substrate Specificity in Human Cytidine Deaminase Family APOBEC3s (2020) (0)
HCV NS3/4A protease domain of genotype 3a in complex with glecaprevir (2020) (0)
Single donor platelet transfusion. (1985) (0)
HIV-1 Protease NL4-3 I13V, G16E, V32I, L33F, K45I, M46I, A71V, V82F, I84V Mutant in complex with darunavir (2019) (0)
Combatting Drug Resistance: Lessons from the viral proteases of HIV and HCV (2014) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-21 (2019) (0)
Crystal structure of HCV NS3/4A protease A156T variant in complex with 5172-Linear (MK-5172 linear analogue) (2016) (0)
Antibody Fab Fragment Complex (2017) (0)
CtBP1 in complex with substrate phenylpyruvate (2015) (0)
Crystal structure of wild-type HIV-1 protease in complex with AF71 (2012) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-6 (NR03-67) (2020) (0)
Combating Drug Resistance: The balance between inhibition and substrate processing (2010) (0)
Crystal Structure of a Nelfinavir Resistant HIV-1 CRF01_AE Protease variant (N88S) in Complex with the Protease Inhibitor Darunavir. (2010) (0)
[The ABO and Rh (D) blood groups in the department of Sarthe]. (1967) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with NR01-129 (2021) (0)
Crystal Structure of inactive single chain variant of HIV-1 Protease in Complex with the substrate p2-NC (2012) (0)
WT HTLV-1 Protease in Complex with UMass6 (UM6) (2021) (0)
HCV NS3/4A protease A156T mutant (2020) (0)
Crystal Structure of wild-type HIV-1 Protease in complex with kd26 (2011) (0)
Crystal structure of inactive HIV-1 protease variant (I50V/A71V) in complex with WT p1-p6 substrate (2014) (0)
HIV-1 Protease NL4-3 WT in Complex with LR-99 (2019) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-42 (2020) (0)
Crystal Structure of wild-type HIV-1 Protease in Complex with DRV (2012) (0)
Crystal structure of protease inhibitor, KB60 in complex with wild type HIV-1 protease (2010) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-41 (2020) (0)
Crystal structure of AD-81 complexed with wild type HIV-1 protease (2006) (0)
Method for Probing at Least One Binding Site of a Protein (2018) (0)
Crystal Structure of Broadly Neutralizing Antibody 3I14 Bound to the Influenza A H10 Hemagglutinin (2020) (0)
Structural Insights into Calmodulation of Neuronal KCNQ Channels (2012) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-4(AJ-74) (2020) (0)
Constraining evolution ⇒ avoiding drug resistance: lessons from viruses (2021) (0)
HIV-1 Protease NL4-3 WT in Complex with Lopinavir (2020) (0)
Crystal structure of a drug-resistant (V82A) inactive (D25N) HIV-1 protease complexed with AP2V variant of HIV-1 NC-p1 substrate. (2006) (0)
Crystal Structure of wild-type HIV-1 Protease in Complex with MKP73 (2012) (0)
Structural Adaptation of Darunavir Analogs Against Primary Resistance Mutations in HIV-1 Protease (2018) (0)
HIV-1 Protease NL4-3 L90M Mutant in complex with darunavir (2019) (0)
Crystal structure of KB73 bound to HIV-1 protease (2007) (0)
1H, 13C, 15N chemical shift assignments for APOBEC3G NTD variant, sNTD (2015) (0)
HCV NS3/4A protease domain of genotype 5a in complex with glecaprevir (2020) (0)
pM to μM: Elucidating the Interdependence of Highly Resistant HIV‐1 Proteases (2019) (0)
Crystal structure of HCV NS3/4A protease in complex with JZ01-15, an analogue of 5172-mcP1P3 (2017) (0)
Crystal Structure of Broadly Neutralizing Antibody 3I14-D93N Mutant Bound to the Influenza A H3 Hemagglutinin (2020) (0)
Crystal structure of HIV-1 Protease NL4-3 V82I Mutant in complex with darunavir (2018) (0)
Crystal structure of HCV NS3/4A protease variant R155K in complex with Asunaprevir (2014) (0)
Amino acid physical chemistry furnishes a two-dimensional basis set for computational structural biology (2017) (0)
HIV-1 Protease NL4-3 WT in Complex with LR-85 (2019) (0)
SARS-CoV-2 Main Protease (Mpro) in Complex with Rupintrivir (P21212) (2021) (0)
Crystal structure of HCV NS3/4A protease A156T variant in complex with 5172-mcP1P3 (MK-5172 P1-P3 macrocyclic analogue) (2016) (0)
Crystal Structure of (G16C/L38C) HIV-1 Protease in Complex with DRV (2012) (0)
Crystal structure of wild-type HIV-1 protease in complex with KB83 (2012) (0)
WT HTLV-1 Protease in Complex with Darunavir (DRV) (2021) (0)
RNA Exclusion Mechanism of the Cytidine Deaminase APOBEC3G (2019) (0)
Crystal structure of HIV-1 Protease NL4-3 WT in complex with darunavir (2018) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-26 (2019) (0)
Crystal structure of dimeric interferon regulatory factor 5 (IRF-5) transactivation domain (2008) (0)
Structural Analysis of Darunavir Analogs Against Primary Resistance Mutations in HIV Protease (2018) (0)
HIV-1 VIF and human APOBEC3G interaction directly observed through molecular specific labeling using a new dual promotor vector. (2022) (0)
Protein Engineering as a tool For Probing Potential Protein Dynamics in HIV-1 Protease (2009) (0)
Crystal structure of Wild-type HIV-1 protease in complex With AF68 (2012) (0)
ALS-causing mutations destabilize the native conformation of Profilin-1 (2015) (0)
Crystal structure of HCV NS3/4A protease variant Y56H in complex with MK-5172 (2019) (0)
The Role of Molecular Recognition in Activation and Regulation in the Growth Hormone-Prolactin Family of Hormones and Receptors (1998) (0)
Crystal structure of wild-type HIV-1 protease in complex with AG23 (2012) (0)
Illuminating the Structural Determinants for Tetrameric Assembly of Oncogenic CtBP to Guide Inhibitor Design (2020) (0)
Crystal structure of lopinavir bound to wild type HIV-1 protease (2007) (0)
CALGB Studies with Hematopoietic Growth Factors in Patients with AML (1992) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-1 (AJ-71) (2019) (0)
HIV-1 Protease NL4-3 WT in Complex with LR3-28 (2020) (0)
Crystal structure of HIV-1 Protease NL4-3 L89V Mutant in complex with darunavir (2019) (0)
Crystal structure of the wild type HIV-1 protease with the inhibitor, Amprenavir (2009) (0)
Crystal Structure of wild-type HIV-1 Protease in complex with kd19 (2011) (0)
CB&DD Editorial Advisory Board (Sixteenth in series) (2007) (0)
Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses (2023) (0)
Crystal structure of HIV-1 Protease NL4-3 I84V Mutant in complex with UMass6 (2018) (0)
Abstract 2233: Structure-based Antiviral Design against HTLV-1 Protease (2023) (0)
EV68 3C protease (3Cpro) in Complex with Rupintrivir (2021) (0)
Robust against Drug Resistance HIV-1 Protease Inhibitors Designed To Be Hypothesis: Structural Analysis of Novel Evaluating the Substrate-Envelope (2014) (0)
HIV-1 Protease NL4-3 WT in Complex with LR3-29 (2020) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-35 (2020) (0)
Crystal Structure of active HIV-1 Protease in Complex with the N terminal product of the substrate MA-CA. (2013) (0)
Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y (2022) (0)
Abstract 1633: C-terminal binding proteins are novel drug targets (2011) (0)
CryoEM Structure of CtBP2 Confirms Tetrameric Architecture (2020) (0)
HIV-1 Protease NL4-3 WT in Complex with LR3-97 (2020) (0)
Crystal Structure of wild-type HIV-1 Protease in complex with af60 (2011) (0)
WT HTLV-1 Protease in Complex with Phosphonated UMass6 (PU6) (2021) (0)
Crystal structure of NS3/4A protease in complex with Asunaprevir (2012) (0)
Crystal structure of APOBEC3A in complex with a single-stranded DNA (2017) (0)
HCV NS3/4A protease domain of genotype 1a D168E in complex with glecaprevir (2020) (0)
Crystal structure of Wild-type HIV-1 protease in complex With AF77 (2012) (0)
HIV-1 Protease NL4-3 WT in Complex with LR4-41 (2020) (0)
Crystal structure of wild-type HIV-1 protease in complex with AF72 (2012) (0)
HIV-1 Protease NL4-3 WT in Complex with LR3-95 (2020) (0)
WT HIV-1 Protease in Complex with Phosphonated UMass6 (PU6) (0)
X-ray crystal structure of HIV-1 Protease T80N variant in complex with the inhibitor saquinavir used to explore the role of invariant Thr80 in HIV-1 protease structure, function, and viral infectivity. (2006) (0)
Crystal Structure of HIV-1 CRF01_AE Protease in Complex with Darunavir (2010) (0)
In Vitro Resistance Development of Oseltamivir Evolution of the Influenza A Virus Genome (2014) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-7 (NR03-77) (2020) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with P4-P5-4 (AJ-65) (2020) (0)
HCV NS3/4A protease A156T mutant in complex with glecaprevir (2020) (0)
Crystal Structure of active HIV-1 Protease in Complex with the N terminal product of CA-p2 cleavage site (2013) (0)
crystal structure of inhibitor amprenavir in complex with a multi-drug resistant variant of HIV-1 protease (L63P/V82T/I84V) (2005) (0)
Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance (2021) (0)
HIV-1 Protease NL4-3 WT in Complex with LR-76 (2019) (0)
HIV-1 Protease NL4-3 WT in Complex with LR-84 (2019) (0)
Cryo‐EM Structure of CtBP2 Confirms Tetrameric Architecture (2020) (0)
Crystal Structure of protease inhibitor, MIT-1-AC86 in complex with wild type HIV-1 protease (2008) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-18 (2019) (0)
Crystal structure of NS3/4A protease variant A156T in complex with MK-5172 (2012) (0)
Bacterial pattern recognition in C. elegans by a nuclear hormone receptor (2022) (0)
Abstract 2735: Pre-emptively Avoiding Drug Resistance: Lessons from viral proteases (2023) (0)
Crystal structure of HCV NS3/4A protease in complex with 5172-mcP1P3 (MK-5172 P1-P3 macrocyclic analogue) (2016) (0)
Crystal structure of wild-type HIV-1 protease in complex with AF80 (2012) (0)
Crystal structure of HCV NS3/4A D168A protease in complex with CH-24 (2021) (0)
Crystal structure of the HIV-1 Vif binding, catalytically active domain of APOBEC3F (2013) (0)
NMR structure of APOBEC3G NTD variant, sNTD (2015) (0)
HIV-1 Protease NL4-3 WT in Complex with LR2-91 (2019) (0)
SARS-CoV-2 Main Protease (Mpro) in Complex with ML188 (2021) (0)
Crystal Structure of wild-type HIV-1 Protease in complex with kd13 (2011) (0)
Crystal Structure of wild type HIV-1 protease in complex with CARB-AD37 (2007) (0)
CtBP1 bound to inhibitor 2-(hydroxyimino)-3-phenylpropanoic acid (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Celia A. Schiffer?

Celia A. Schiffer is affiliated with the following schools:

University of California, Berkeley
University of Oxford
Massachusetts Institute of Technology
University of Chicago
University of Massachusetts Medical School
University of California, San Francisco
University of Massachusetts